ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effects of Qushuanling Capsule ( QSLC) on thrombus formation and platelet aggregation in rats.</p><p><b>METHODS</b>Arteriovenous bypass, venous thrombosis, and middle cerebral artery thrombosis models were used in rats to investigate the anti-thrombotic effects of QSLC, a compound of nine Chinese herbs. The platelet aggregation induced by adenosine diphosphate (ADP), thrombin or arachidonic acid (AA), as well as the contents of thromboxane B(2) (TXB(2)) and 6-keto-prostaglandin F1α (6-keto-PGF1α) in rat plasma and aortic walls, were determined to investigate the possible mechanisms of the anti-thrombotic effects of QSLC.</p><p><b>RESULTS</b>After oral administration with QSLC for 7 days, arteriovenous bypass thrombosis was obviously suppressed compared with the model group, venous thrombosis was also obviously suppressed, rat behaviors were obviously improved, and brain infarct size as well as water content were also reduced. The platelet aggregation induced by ADP or thrombin was inhibited by QSLC, but the drug had no effect on AA-induced platelet aggregation and content of TXB(2) and 6-keto-PGF1α in plasma and the aortic wall.</p><p><b>CONCLUSION</b>These results suggest that QSLC can be used in the prevention and treatment of thrombotic diseases, and that its mechanism of action may be related to inhibition of platelet aggregation.</p>
Subject(s)
Animals , Male , Rats , 6-Ketoprostaglandin F1 alpha , Blood , Adenosine Diphosphate , Pharmacology , Aorta , Metabolism , Pathology , Cerebral Infarction , Blood , Drug Therapy , Pathology , Drugs, Chinese Herbal , Pharmacology , Therapeutic Uses , Middle Cerebral Artery , Pathology , Platelet Aggregation , Rats, Sprague-Dawley , Thrombosis , Drug Therapy , Pathology , Thromboxane B2 , Blood , Venous Thrombosis , Drug Therapy , PathologyABSTRACT
<p><b>OBJECTIVE</b>To investigate the variety of vitro recovery of amino acids for microdialysis probe after different dialysis time in vivo.</p><p><b>METHODS</b>Probes were dialyzed in the amino acids standard solutions with microdialysis system,amino acid standard solutions and the microdialysate of probe were detected by the method of precolumn derivation with HPLC-RF.</p><p><b>RESULT</b>After using different time of probe made by regenerated cellulose membrane, the vitro recoveries of Asp, Glu and GABA were not completely same (Asp: F=19.669, P=0.000; Glu: F=103.955, P=0.000; GABA: F=3.454, P=0.040); while the vitro recovery of Tau had no obvious difference(F=2.001, P=0.152). After using 6 h in vivo, recovery remain percentage (RRP) of Asp, Glu,Tau and GABA was 64.34 %, 67.36%, 103.11 % and 98.23 %, respectively, the recoveries of Asp, Glu decreased obviously (Asp: P < 0.01,Glu: P <0.05). After using 12 h in vivo, the RRP of Asp, Glu, Tau and GABA was 43.44 %, 24.42%, 77.45 % and 67.36 %, respectively, the recoveries of Asp, Glu and GABA decreased obviously (Asp: P < 0.001, Glu: P < 0.001, GABA: P < 0.05). After using 24 h in vivo, the RRP of Asp, Glu,Tau and GABA was 36.26 %, 12.24 %, 89.48 % and 71.35 %, respectively, the recoveries of Asp, Glu, GABA decreased obviously (Asp: P < 0.0001, Glu: P < 0.0001, GABA: P < 0.01).</p><p><b>CONCLUSION</b>Dialysis in vivo could lead to the decline of recovery of probe, the decline is more obvious after longer dialysis. So when making brain dialysis experiments, the use time of probe should not be too long. To improve the validity of data, some calibration should be made on the recoveries of probe.</p>